What's in Hansa Biopharma AB's pipeline?

Hansa Biopharma AB has 4 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Hansa Biopharma AB's portfolio?

Top competitors by shared drug class: Alberta Health services, Asahi Kasei Pharma Corporation, Assistance Publique - Hôpitaux de Paris, Astellas Pharma China, Inc., Baxter.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hansa-biopharma-ab.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Hansa Biopharma AB — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hansa Biopharma AB pipeline: 3 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ides	IMLIFIDASE	marketed		Immunoglobulin gamma (IgG), heavy chain	Immunology	2020-01-01
Anti-CD20 antibodies	Anti-CD20 antibodies	marketed
Cyclophosphamide (CYC)	Cyclophosphamide (CYC)	marketed	Alkylating agent	DNA	Oncology, Immunology

Therapeutic area mix

Immunology · 1
Oncology, Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alberta Health services · 1 shared drug class
Asahi Kasei Pharma Corporation · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Astellas Pharma China, Inc. · 1 shared drug class
Baxter · 1 shared drug class
BeBetter Med Inc · 1 shared drug class
Celyad Oncology SA · 1 shared drug class
Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hansa Biopharma AB:

Cite this brief

Drug Landscape (2026). Hansa Biopharma AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hansa-biopharma-ab. Accessed 2026-05-16.